scholarly journals High expression of protein phosphatase 2 regulatory subunit B'' alpha predicts poor outcome in hepatocellular carcinoma patients after liver transplantation

2021 ◽  
Vol 13 (7) ◽  
pp. 716-731
Author(s):  
Jia-Jia He ◽  
Lei Shang ◽  
Qun-Wei Yu ◽  
Ning Jiao ◽  
Shuang Qiu ◽  
...  
2019 ◽  
Vol 8 (18) ◽  
pp. 7741-7753 ◽  
Author(s):  
Huijuan Chen ◽  
Jing Xu ◽  
Peixiao Wang ◽  
Qingming Shu ◽  
Lihong Huang ◽  
...  

2011 ◽  
Vol 156 (3) ◽  
pp. 1464-1480 ◽  
Author(s):  
Andrea Trotta ◽  
Michael Wrzaczek ◽  
Judith Scharte ◽  
Mikko Tikkanen ◽  
Grzegorz Konert ◽  
...  

2019 ◽  
Vol 20 (11) ◽  
pp. 2748 ◽  
Author(s):  
Yaning Wang ◽  
Chugang Mei ◽  
Xiaotong Su ◽  
Hongbao Wang ◽  
Wucai Yang ◽  
...  

Understanding the molecular mechanisms of skeletal myoblast differentiation is essential for studying muscle developmental biology. In our previous study, we reported that knockdown of myocyte enhancer factor 2A (MEF2A) inhibited myoblast differentiation. Here in this study, we further identified that MEF2A controlled this process through regulating the maternally expressed 3 (MEG3)—iodothyronine deiodinase 3 (DIO3) miRNA mega cluster and protein phosphatase 2A (PP2A) signaling. MEF2A was sufficient to induce MEG3 expression in bovine skeletal myoblasts. A subset of miRNAs in the MEG3-DIO3 miRNA cluster was predicted to target PP2A subunit genes. Consistent with these observations, MEF2A regulated PP2A signaling through its subunit gene protein phosphatase 2 regulatory subunit B, gamma (PPP2R2C) during bovine myoblast differentiation. MiR-758 and miR-543 in the MEG3-DIO3 miRNA cluster were down-regulated in MEF2A-depleted myocytes. Expression of miR-758 and miR-543 promoted myoblast differentiation and repressed PPP2R2C expression. Luciferase activity assay showed that PPP2R2C was post-transcriptionally targeted by miR-758 and miR-543. Taken together, these results reveal that the MEG3-DIO3 miRNAs function at downstream of MEF2A to modulate PP2A signaling in bovine myoblast differentiation.


2014 ◽  
Vol 205 (3) ◽  
pp. 1250-1263 ◽  
Author(s):  
Grzegorz Konert ◽  
Andrea Trotta ◽  
Petri Kouvonen ◽  
Moona Rahikainen ◽  
Guido Durian ◽  
...  

FEBS Letters ◽  
1996 ◽  
Vol 379 (1) ◽  
pp. 107-111 ◽  
Author(s):  
Osamu Tanabe ◽  
Terumasa Nagase ◽  
Takehiko Murakami ◽  
Hideto Nozaki ◽  
Hirofumi Usui ◽  
...  

2021 ◽  
Author(s):  
Priyanka Madaan ◽  
Amrit Kaur ◽  
Lokesh Saini ◽  
Pradip Paria ◽  
Sameer Vyas ◽  
...  

Abstract Background Protein phosphatase 2 regulatory subunit B′ delta (PPP2R5D)-related neurodevelopmental disorder is caused by pathogenic variations in the PPP2R5D gene, product of which is involved in dephosphorylation. This is a rare disorder with description limited to case reports. Its phenotypic spectrum has expanded over the last decade. Methods We report a child with a developmental and epileptic encephalopathy phenotype with a pathogenic PPP2R5D variant. This phenotype has not been previously reported. We also reviewed the previously published reports of patients with this disorder. Results Including the index child, 28 cases (15 girls) were identified from nine relevant research items for analysis. All patients had developmental delay. History of seizures was observed in seven patients while macrocephaly was seen in nearly 80% of patients. Nonneurological manifestations were observed in 13 patients with the most common one being ophthalmological manifestations. The most common genetic variation was c.G592A (p.E198K). The common phenotypic associations of this variation were developmental delay, macrocephaly (11/15), and epilepsy (6/15). Conclusion PPP2R5D gene variations should be suspected in children with developmental delay, autistic features, macrocephaly with or without epilepsy in the absence of any clear etiology. Dysmorphic features might provide a diagnostic clue. DEE phenotype may also be the presenting feature and might be an underreported entity.


Sign in / Sign up

Export Citation Format

Share Document